| Date Filed | Type | Description |
| 02/17/2015 |
SC 13G/A
| RA CAPITAL MANAGEMENT, LLC reports a 0% stake in Furiex Pharmaceuticals, Inc. |
| 02/17/2015 |
SC 13G/A
| Consonance Capital Management LP reports a 0% stake in Furiex Pharmaceutical, Inc |
| 02/06/2015 |
SC 13G/A
| THOMPSON SIEGEL & WALMSLEY LLC reports a 0% stake in FURIEX PHARMACEUTICALS INC. |
| 07/08/2014 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/07/2014 |
SC 13D
| Magnetar Financial LLC reports a 10% stake in Furiex Pharmaceuticals, Inc. |
| 07/03/2014 |
8-K
| Form 8-K - Current report |
| 07/03/2014 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/01/2014 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/23/2014 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/16/2014 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/04/2014 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 05/28/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/09/2014 |
10-Q
| Quarterly Report for the period ended March 31, 2014 |
| 05/09/2014 |
SC 13G
| MORGAN STANLEY reports a 5.3% stake in FURIEX PHARMACEUTICALS, INC. |
| 05/07/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/29/2014 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/28/2014 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty" |
|
| 04/28/2014 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 04/11/2014 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 04/11/2014 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
| 03/17/2014 |
10-K
| Annual Report for the period ended December 31, 2013 |
| 03/11/2014 |
8-K
| Quarterly results |
| 02/14/2014 |
SC 13G/A
| Invus Public Equities, L.P. reports a 8.4% stake in FURIEX PHARMACEUTICALS, INC. |
| 02/14/2014 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 3.1% stake in Furiex Pharmaceuticals, Inc. |
| 02/13/2014 |
SC 13G
| Consonance Capital Management LP reports a 6.3% stake in Furiex Pharmaceutical, Inc |
| 02/11/2014 |
SC 13G/A
| BlackRock Inc. reports a 4.5% stake in FURIEX PHARMACEUTICALS INC. |
| 02/06/2014 |
SC 13G
| THOMPSON SIEGEL & WALMSLEY LLC reports a 5.8% stake in FURIEX PHARMACEUTICALS INC. |
| 02/05/2014 |
SC 13G
| RA CAPITAL MANAGEMENT, LLC reports a 7.2% stake in Furiex Pharmaceuticals, Inc. |
| 02/04/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/06/2013 |
8-K/A
| Financial Statements and Exhibits |
| 11/12/2013 |
10-Q
| Quarterly Report for the period ended September 30, 2013 |
| 11/05/2013 |
8-K
| Quarterly results |
| 11/01/2013 |
8-K
| Form 8-K - Current report |
|